Kylie Keijzer

Kylie Keijzer is a researcher actively contributing to oncology, hematology, and immunotherapy. Her work focuses on improving clinical outcomes through studies on CAR T-cell therapy for large B-cell lymphoma, tumor volume analysis, and toxicity risk profiling in head and neck cancer patients. She has also investigated metabolic complications like severe hyperglycemia during hematological care.

Research areas include:

• Development of Normal Tissue Complication Probability (NTCP) models for head and neck cancer
• Role of serum TARC as a biomarker in Hodgkin lymphoma relapse detection
• Metabolic active tumor volume control to enhance CAR T-cell therapy survival outcomes
• Prospective glucose monitoring studies in hematological patients

Her collaborations span international institutions, aligning with UN Sustainable Development Goals related to health and well-being (SDG 3) and global partnerships (SDG 17).